Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06770010 · ClinicalTrials.gov registry record · NA

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

A NA study of Sickle Cell Disease, sponsored by Children's National Research Institute.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06770010: Recruiting NA study of Sickle Cell Disease, sponsored by Children's National Research Institute.

NCT06770010 is a NA study of Sickle Cell Disease that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 50 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06770010, a NA study of Sickle Cell Disease, is actively recruiting participants, sponsored by Children's National Research Institute.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle cell disease ages 7-16 years.

Primary Outcome

At least 75% of participants will complete 10 or more Cogmed training sessions.

Conditions Studied

Interventions

  • BEHAVIORAL Cogmed+

Study Locations (1)

District of Columbia

  • Children's National Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-03-05
Est. Completion 2026-04-01
Phase NA

What NCT06770010 shows while recruiting

NCT06770010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Cogmed+ is the first listed.

NCT06770010 reports a single indexed study location in District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06770010 about?

NCT06770010 is a clinical study titled "Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease". This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle cel...

What is the current status of trial NCT06770010?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-03-05. Estimated completion is 2026-04-01.

What conditions does trial NCT06770010 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT06770010?

The interventions under investigation include: Cogmed+ (BEHAVIORAL).

Who is sponsoring clinical trial NCT06770010?

This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06770010 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06770010's enrollment target sits among peer trials

50 106th of 213 higher than 100 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06770010, the US trial registry maintained by the National Library of Medicine. NCT06770010 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.